PAPILLON Study: Amivantamab Plus Chemotherapy in EGFR-mutated NSCLC

The PAPILLON trial compared the combination of amivantamab plus chemotherapy with chemotherapy alone in patients with EGFR exon 20 insertion-mutated advanced NSCLC. Combination treatment resulted in a 60% reduction in the risk for progression or death compared with chemotherapy alone (HR, 0.395; 95% CI, 0.30-0.53; P<.001). Adverse events with amivantamab plus chemotherapy led to dose interruptions in almost 70% of patients and dose reductions in almost 50%.

Read the full study.

Review more high-impact trials benefitting the growing number of patients with advanced NSCLC who have genomic alterations.